---
schema_version: "secwatch.filing_event.v1"
accession: "0001562762-22-000444"
form_type: "8-K"
ticker: "GMED"
cik: "0001237831"
company_name: "GLOBUS MEDICAL INC"
filed_at: "2022-11-08T23:59:59+00:00"
generated_at: "2026-06-22T02:58:38.073725+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Globus Medical Q3 net sales $254.1M (+10.6% YoY); lowers FY22 non-GAAP EPS guidance to $2.03

## Summary
- Q3 net sales $254.1M, up 10.6% as-reported and 12.6% constant currency; GAAP net income $47.4M, +0.5% YoY.
- GAAP diluted EPS $0.47, non-GAAP diluted EPS $0.50; non-GAAP adjusted EBITDA $82.8M (32.6% of sales).
- U.S. Spine sales +9.0%, International Spine +11.1% as-reported (+24.8% constant currency); Enabling Technologies +19.0% to $24.1M.
- FY 2022 net sales reaffirmed at $1.025B; non-GAAP diluted EPS guidance lowered to $2.03 from $2.10 due to currency and tax.
- Company remains debt-free; operating cash flow $32.9M and free cash flow $20.9M in Q3.

## SEC filing metadata
- accession: 0001562762-22-000444
- form_type: 8-K
- ticker: GMED
- cik: 0001237831
- company_name: GLOBUS MEDICAL INC
- filed_at: 2022-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1237831/000156276222000444/0001562762-22-000444-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1237831/000156276222000444/gmed-20221108x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001562762-22-000444
- JSON: https://secwatch.observer/filing/0001562762-22-000444.json
- Plain text: https://secwatch.observer/filing/0001562762-22-000444.txt

## Key facts
- Earnings Releases
  GLOBUS MEDICAL INC reported quarter ended September 30, 2022 results: revenue $254.1 million, net income $47.4 million, EPS $0.47. Guidance reaffirmed.
  - Period: quarter ended September 30, 2022
  - Revenue: $254.1 million
  - Net income: $47.4 million
  - EPS: $0.47
  - Guidance: reaffirmed
  - Result: reported results
  source text: Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended September 30, 2022 .  · Worldwide net sales were $254.1 million , an increase of 10.6% , or 12.6% on a constant currency basis · GAAP net income for the quarter was $47.4 million · GAAP d iluted earnings per share (“ EPS ”) was $0.47 and
  evidence_url: https://www.sec.gov/Archives/edgar/data/1237831/000156276222000444/0001562762-22-000444-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.